Bristol Myers buys Nvidia’s latest AI computing system for drug research

Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia to support its use of artificial intelligence across its drug discovery and development operations.

The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD based on its Vera Rubin systems. ‌The chipmaker ⁠unveiled its ⁠Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.